BioSpace News Archive

Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies for autoimmune diseases and gene therapies, today reported financial results for the second quarter ended June 30, 2023 and provided a business update.

Foresight Diagnostics, a leading provider of ultrasensitive cancer detection tests, today announced the appointment of John Truesdell as Chief Business Officer.

Element Biosciences, Inc. today unveiled five new products to better serve customers’ low to medium-throughput needs and expand the functionality and versatility of its benchtop sequencer.

RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today provided first half, 2023, financial results and operational highlights.

Coeptis Therapeutics Holdings, Inc. announced that it has completed the exclusive license of key assets from Deverra Therapeutics Inc. (“Deverra”) related to its proprietary allogeneic stem cell expansion and directed differentiation platform for the generation of multiple distinct immune effector cell types, including natural killer (NK) and monocyte/macrophages.

PetVivo Holdings, Inc. an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals is pleased to announce that the United States Patent and Trademark Office has issued a notice of allowance for a patent application related to the Company’s proprietary biocompatible protein-based particles.

Roche announced that it has a new addition to the cobas® connection modules, the CCM Vertical, allowing transportation of samples on overhead conveyors.* This solution allows for CCM conveyors to cross walkways, connecting different work areas and keeps exits accessible.

AbbVie announced that the European Commission has approved AQUIPTA® for the prophylaxis of migraine in adults who have four or more migraine days per month.

Caris Life Sciences®, the leading next-generation TechBio company and precision medicine pioneer that is actively developing and delivering innovative solutions to revolutionize healthcare and improve the human condition, announced that UC Davis Comprehensive Cancer Center has joined the Caris Precision Oncology Alliance™.

I-Mab announced its financial results for the six months ended June 30, 2023, and provided key business updates.